Global /Japan /Healthcare /Drug Manufacturers - General /4880

CellSource Co., Ltd.

4880

• TSE: 4880 • Delayed

367JPY -2.9%

2.29 USD

As of 5 June 2026, CellSource Co., Ltd. has a market cap of $46.88M USD, ranking #31071 globally and #2905 in Japan. It ranks #2804 in the Healthcare sector, and #979 in the Drug Manufacturers - General industry.

Global Rank

31071

Country Rank

2905

Sector Rank

2804

Industry Rank

979

Key Stats

Market Cap

$46.88MUSD

7.5B JPY

Enterprise Value

$17.98MUSD

2.88B JPY

Revenue (TTM)

$23.26MUSD

3.72B JPY

Net Income (TTM)

$556.67KUSD

89.08M JPY

PE Ratio

84.1

Forward PE

73.8

PS Ratio

2.0

PB Ratio

1.3

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Masayuki Yamakawa open_in_new

Employees

148

Founded

2015

Website

cellsource.co.jp open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.9%	-4.1%	-2.6%	-5.7%	-28%	-5.3%	-42%	-86%	-91%

Upcoming Earnings

Earnings Date

Fri, Jun 12

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4880 セルソース株式会社 ISIN: JP3423580004 Shares Out.: Shares Outstanding: 19.847M¹ Shares Float: 9.1M² TV: TradingView: TSE: 4880 SA: Stock Analysis: TYO: 4880 YF: Yahoo Finance: 4880.T GF: Google Finance: TYO: 4880 BA: Barron's: 4880 MS: Morningstar: XTKS: 4880	367 JPY	TV: TradingView: TSE: 4880 SA: Stock Analysis: TYO: 4880 YF: Yahoo Finance: 4880.T GF: Google Finance: TYO: 4880 BA: Barron's: 4880 MS: Morningstar: XTKS: 4880

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CellSource Co., Ltd.

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.66B 13.07T JPY 174K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.21B 8.36T JPY 111K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.84B 5.9T JPY 78K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.37B 4.86T JPY 65K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.82B 4.13T JPY 55K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.91B 2.71T JPY 36K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 769K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 692K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 617K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 591K%	20.5	Switzerland

chevron_leftBack